Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Supportive Care for Patients With Guillain-Barr Syndrome
Arch Neurol 62:1194-1198, Hughes,R.A.C.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Cost-Effectiveness Analysis:What Is It and How Will It Influence Neurology
Ann Neurol 39:818-823, Holloway,R.G., 1996
Lyme Neuroborreliosis
Ann Neurol 37:691-702, Garcia-Monco,J.C.&Benach,J.L., 1995
Autonomic Involvement in Guillain-Barre Syndrome:A Review
Muscle & Nerve 17:1145-1155994., Zochodne,D.W., 1994
Intensive Management and Treatment of Severe Guillain-Barre Syndrome
Crit Care Med 21:433-446, Hund,E.F.,et al, 1993
Guillain-Barre Syndrome After Streptokinase Therapy
Acta Neurologica Scand 82:153, Roquer,J.,et al, 1990
Hypophosphatemia Mimicking Acute Guillain-Barre-Strohl Syndrome
JAMA 235:1040-1041, Weintraub,M.I., 1976
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Acute Areflexic Paralysis
Arch Neurol 32:706, Furlan,A.J.,et al, 1975